Research & Development
Italfarmaco is an important player in the pharma industry landscape due to both, its products and its R&D activities.
The first molecule developed in its Research Center was marketed in 1984. Subsequently, a protein iron complex was developed for the treatment of anemia resulting from iron deficiency, today marketed in over 40 countries worldwide. In 1988, the company began marketing a treatment for cerebral cognitive disorders, while also overseeing its international development, particularly for the management of both vascular and non-vascular forms of Alzheimer’s disease. In the cardiovascular area it was a pioneer in the development of antithrombotic drugs in the chronic treatment of ischemic heart disease and in the prophylaxis and therapy of venous and arterial thrombosis.
Our present research is centered around neuromuscular disorders, fibrosis and cancer (including oncology supportive care) with a special focus on rare diseases. While our capabilities span three treatment modalities: small molecules, peptides, and monoclonal antibodies, selected to best match the biology of the target, the distinctive feature of the Italfarmaco R&D group lies in its expertise in a specific family of enzymes involved in the post-translational modification of proteins and polyamines.
Our research focuses on the modulation of key biological processes involved in the regulation of gene expression, with the potential to reprogram cell fate. Our most advanced compound has recently received FDA and EMA approvals for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged six years and older, and is also in late-stage clinical development for Polycythemia Vera, a rare hematologic cancer. Our R&D team is currently working on the development of next-generation, highly selective compounds designed to target specific biological pathways with greater precision.
In addition to the development of new chemical entities, Italfarmaco’s R&D group also develops new formulations of established drugs to better respond to patient needs and generics/biosimilars of complex molecules. Examples developed up to market in Europe, USA and Rest of the World are the liquid formulations of antidepressants or hypnotic agents for the treatment of Amiotrophic Lateral Sclerosis (ALS).
Our Focus
The goal of Italfarmaco’s research activity is to provide caregivers and patients with effective and safe drugs, to improve the health and to ensure a better quality of life of patients.
Our Focus
The goal of Italfarmaco’s research activity is to provide caregivers and patients with effective and safe drugs, to improve the health and to ensure a better quality of life of patients.
Our Focus
The goal of Italfarmaco’s research activity is to provide caregivers and patients with effective and safe drugs, to improve the health and to ensure a better quality of life of patients.
